2. BB: IntroVAE
n fdp
n A 1 ) A 5 A9 5 12 92A9 2: A 5 45
/8 A 2 89 2 5 0 A85 9
n A 5 A9 5 VGlg I o
n N /0 45 5 95 /0V( mn
n
n eSa cP 1 E / SI
i h
22018/9/2
5. BB: VAE GAN
n ( V N G ( d a
V E a ) LV
n ( sr N N AD
V oADV mADV
n Nd ] L 1 N [ c
V N V
n r i nA GG sr e V
1 1 V
52018/9/2
VAE GAN
Pro m ] V t L
Con V m ] L
6. BB: VAE
n ) h n G_ ]
(
n e I V AR n GA
n (
n
n ) L V mn A
n
n + E = I[ G
62018/9/2
7. BB: adversarial distribution matching
n a ed
n (
• ed ed) E G
• ed ed) E G
n ( (
• ed ed) E G
n G D
ed E G c
72018/9/2
11. BB:
n 4 4 H ED
n 4 4 H ED
n 12- 0 12- C: B AD
112018/9/2
training validation testing
CelebA 162770 19867 19962
CelebA-HQ 29000 - 1000
LSUN(Bedroom) 3033042 - -